In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.

@article{Sutton1999InVA,
  title={In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.},
  author={Deanna A. Sutton and S E Sanche and Sanjay G Revankar and Annette W. Fothergill and Michael G. Rinaldi},
  journal={Journal of clinical microbiology},
  year={1999},
  volume={37 7},
  pages={2343-5}
}
Amphotericin B therapy continues to be the "gold standard" in the treatment of invasive aspergillosis in the immunocompromised host. Although Aspergillus fumigatus and Aspergillus flavus constitute the major species, several reports have described invasive pulmonary or disseminated disease due to the less common Aspergillus terreus and dismal clinical outcomes with high-dose amphotericin B. We therefore evaluated 101 clinical isolates of A. terreus for their susceptibility to amphotericin B and… CONTINUE READING